Comparative Pharmacology
Head-to-head clinical analysis: AURLUMYN versus FLUDARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURLUMYN versus FLUDARA.
AURLUMYN vs FLUDARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateFludarabine + Digoxin
"Fludarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFludarabine + Digitoxin
"Fludarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFludarabine + Deslanoside
"Fludarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFludarabine + Acetyldigitoxin
"Fludarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Fludarabine phosphate: 0.7-1 h (rapid dephosphorylation). Active metabolite 2-fluoro-ara-A: terminal t1/2 20-30 h (up to 40 h in renal impairment).
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Renal: 60% excreted unchanged in urine; biliary/fecal: <5% as metabolites.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent